A first administration, not a proven treatment

A patient in the UK has received a personalised therapeutic vaccine for advanced non-small-cell lung cancer in the NEOVACC clinical trial, marking the first administration of the study treatment in the country. The event is an important translational milestone: it moves a tumour-tailored DNA vaccine from laboratory development into patient testing.

It should not, however, be read as evidence that the vaccine has treated the cancer successfully. NEOVACC is a small, early-stage phase I study. Its central question is whether an individualised vaccine can be produced and supplied in time for treatment, while safety, tolerability, immune responses and signs of anti-tumour activity are secondary or exploratory measures.

The trial is led by researchers and clinicians at the Clatterbridge Cancer Centre and the University of Liverpool, with the Liverpool Clinical Trials Centre involved in its delivery. It is publicly funded through the Medical Research Council, part of UK Research and Innovation. The study is intended to enrol ten people with advanced non-small-cell lung cancer.

What is being personalised

Therapeutic cancer vaccines differ from preventive vaccines. They are given to people who already have cancer and are intended to help the immune system identify and attack tumour cells. In NEOVACC, the targets are genetic alterations found in an individual participant’s tumour rather than a standard set of tumour markers shared by many patients.

Researchers analyse tumour material to identify mutations that may create neoantigens: altered protein fragments that can potentially distinguish cancer cells from normal tissue. The personalised vaccine is designed to present selected tumour-specific targets to the immune system, with the aim of prompting or strengthening a T-cell response against cells carrying those changes.

This premise addresses a major challenge in cancer immunotherapy. Immune-checkpoint medicines such as pembrolizumab can release brakes on anti-cancer immune activity, but some tumours remain insufficiently recognised by the immune system or eventually escape immune control. A vaccine may, in principle, provide the immune system with clearer targets while checkpoint blockade supports the resulting immune response.

The strategy is not designed to replace standard treatment in this study. Participants receive the investigational vaccine alongside anti-PD-1 immunotherapy, specifically pembrolizumab under the trial protocol. Eligible patients have advanced or recurrent non-small-cell lung cancer with high PD-L1 expression and must have had at least three cycles of standard immunotherapy without complete tumour clearance.

Why the manufacturing method matters

The vaccine uses a DNA platform called doggybone DNA, or dbDNA. Unlike conventional plasmid DNA production, which relies on bacterial fermentation, the material is made enzymatically in a cell-free process. The researchers hope that this can shorten and simplify the production of bespoke DNA vaccines.

Manufacturing is a central practical obstacle for personalised cancer vaccination. Every patient’s treatment requires tumour sequencing, target selection, vaccine design, production, quality checks and delivery before the disease progresses or treatment plans must change. A scientifically promising vaccine that cannot be manufactured on a clinically useful timetable would have limited value in routine care.

For that reason, the NEOVACC trial’s primary endpoint is operational as much as biological: whether the patient-specific vaccine can be made and delivered by the time of the first vaccination. The study will also monitor adverse events, tumour response on scans, time to progression, survival and immune measures in blood and tissue.

The vaccine is administered intramuscularly through a needle-free injection system. The protocol provides for doses every three weeks during the initial 24 weeks and then every six weeks, given before standard anti-PD-1 treatment, for up to 18 vaccinations over two years.

A deliberately narrow first study

The trial’s design reflects the uncertainty inherent in first-in-human testing of this particular personalised dbDNA vaccine. It is a single-arm, non-randomised study, meaning there is no control group receiving standard treatment alone. That makes it unsuitable for establishing whether the vaccine extends survival or outperforms existing care.

Its small size also matters. Results from ten participants could show that the logistics are feasible and identify immediate safety concerns, but they would not settle questions about clinical benefit or reliably identify uncommon side effects. If the study produces encouraging feasibility, safety and immune-response results, larger comparative trials would still be needed.

The protocol also excludes people whose cancer is progressing too rapidly to wait for vaccine production. This is ethically and clinically understandable, but it means that findings will apply only to a carefully selected group of patients who are well enough for extra biopsies, monitoring and a personalised manufacturing interval.

The evidence gap for lung-cancer vaccines

The scientific rationale is credible, but the history of therapeutic vaccines in advanced lung cancer calls for caution. A recent systematic review of randomised trials found that earlier vaccine approaches generally did not improve overall survival or progression-free survival by meaningful amounts. The evidence varied in quality and involved different vaccine technologies, treatment settings and patient populations.

NEOVACC should therefore be viewed as a new technical and biological approach rather than a confirmation that cancer vaccines work in this disease. Its individualised targets and combination with checkpoint inhibition distinguish it from many prior studies, but they do not remove the need for rigorous testing.

Non-small-cell lung cancer is the most common broad category of lung cancer, accounting for roughly four in five cases. The continuing burden of lung cancer and the limited durability of treatment responses for many people explain the interest in strategies that can make immune therapies more precise and more persistent.

What success would look like next

Near-term success for NEOVACC would mean that bespoke vaccines can be generated consistently, administered alongside pembrolizumab without unacceptable toxicity and shown to stimulate measurable tumour-directed immune activity. Tumour shrinkage or durable disease control in some participants would be encouraging, but would remain preliminary in a study of this size.

The longer-term question is whether such a platform can be made rapidly, affordably and reliably enough to support larger trials and, eventually, broader NHS use. Personalisation has the potential to improve target specificity, yet it also adds complexity at every stage from sequencing to supply.

For now, the first UK administration is best understood as the beginning of a feasibility and safety test, not the arrival of a new standard therapy. Its value lies in whether it can generate the evidence needed to decide if a personalised DNA vaccine deserves to advance to more definitive clinical evaluation.

Sources